FTI Consulting
FCN
137.73
+0.12
+0.09%
FTI Consulting
US · FCN
#2316 by market cap
Listed 1970
137.73
+0.12
+0.09%
Live - 5344 symbols - heartbeat 269s ago
· 2026-10-07 20:02
After-hours
137.73
0.00%
- Market cap
- 3.80B
- P/E (TTM)i
- 16.67
- P/Bi
- 2.85
- EPSi
- 8.24
- Div yieldi
- 0.00%
- 52W posi
- 14%
Reader sentiment
Are you bullish or bearish on FCN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.71, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +2.44% YoY
Margins
- Gross margin
- 32.13%
- Operating margin
- 10.94%
- Net margin
- 7.15%
Key ratios & quality
- Enterprise valuei
- 3.94B
- PEG ratioi
- 3.49
- Altman Z-Scorei
- 3.71
PEG uses trailing P/E against the 3-year net income growth rate (4.77%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.03B | 2.35B | 2.46B | 2.78B | 3.03B | 3.49B | 3.70B | 3.79B |
| Gross profit | 699.80M | 817.82M | 788.56M | 860.72M | 962.93M | 1.14B | 1.18B | 1.22B |
| Selling & admin expenses | 465.64M | 504.07M | 488.41M | 537.84M | 641.07M | 751.31M | 822.15M | 799.62M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 226.01M | 305.60M | 289.77M | 312.05M | 312.22M | 377.56M | 355.59M | 414.37M |
| Pretax profit | 207.79M | 288.45M | 262.45M | 297.95M | 297.75M | 358.36M | 350.77M | 371.01M |
| Tax | 57.18M | 71.72M | 51.76M | 62.98M | 62.24M | 83.47M | 70.68M | 100.14M |
| Net profit | 150.61M | 216.73M | 210.68M | 234.97M | 235.51M | 274.89M | 280.09M | 270.87M |
| Basic EPS | 4 | 6 | 6 | 7 | 7 | 8 | 8 | 8 |
| Diluted EPS | 3.93 | 5.69 | 5.67 | 6.65 | 6.58 | 7.71 | 7.81 | 8.24 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 898.28M | 943.66M | 956.17M | 990.75M | 983.35M | 993.46M |
| Gross profit | 289.35M | 302.52M | 317.93M | 307.67M | 306.83M | 316.27M |
| Selling & admin expenses | 184.34M | 202.20M | 199.48M | 213.60M | 222.30M | 230.71M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 104.00M | 99.26M | 117.67M | 93.44M | 83.92M | 85.02M |
| Pretax profit | 80.58M | 91.94M | 111.73M | 86.76M | 78.55M | 72.99M |
| Tax | 18.76M | 20.24M | 28.91M | 32.23M | 20.92M | 15.18M |
| Net profit | 61.82M | 71.70M | 82.82M | 54.53M | 57.63M | 57.81M |
| Basic EPS | 2 | 2 | 3 | 2 | 2 | 2 |
| Diluted EPS | 1.74 | 2.13 | 2.60 | 1.78 | 1.90 | 1.99 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 965.35M | 1.18B | 1.13B | 1.37B | 1.51B | 1.56B | 1.82B | 1.52B |
| Cash & ST investments | 312.07M | 369.37M | 294.95M | 494.49M | 491.69M | 328.68M | 660.49M | 265.09M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 2.38B | 2.78B | 2.78B | 3.10B | 3.24B | 3.33B | 3.60B | 3.49B |
| Total current liabilities | 482.57M | 612.54M | 670.17M | 718.12M | 769.49M | 892.77M | 931.76M | 975.19M |
| Short-term debt | -- | 35.73M | 42.72M | 30.83M | 31.92M | 33.86M | 34.11M | 37.21M |
| Long-term debt | 265.57M | 275.61M | 286.13M | 297.16M | 315.17M | -- | -- | 365.00M |
| Total liabilities | 1,030,296,000.00 | 1,294,000,000.00 | 1,377,182,000.00 | 1,517,588,000.00 | 1,559,686,000.00 | 1,344,458,000.00 | 1,338,540,000.00 | 1,756,797,000.00 |
| Total equity | 1.35B | 1.49B | 1.40B | 1.58B | 1.68B | 1.98B | 2.26B | 1.73B |
| Retained earnings | 1.20B | 1.41B | 1.51B | 1.70B | 1.86B | 2.11B | 2.39B | 1.86B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.43B | 1.50B | 1.50B | 1.52B | 1.56B | 1.59B |
| Cash & ST investments | 151.12M | 152.83M | 145.97M | 265.09M | 198.28M | 163.75M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 3.35B | 3.49B | 3.49B | 3.49B | 3.51B | 3.53B |
| Total current liabilities | 637.29M | 713.50M | 809.04M | 975.19M | 676.83M | 782.39M |
| Short-term debt | -- | -- | -- | 37.21M | -- | -- |
| Long-term debt | 160.00M | 470.00M | 510.00M | 365.00M | 754.26M | 1.02B |
| Total liabilities | 1,198,064,000.00 | 1,594,279,000.00 | 1,740,130,000.00 | 1,756,797,000.00 | 1,844,831,000.00 | 2,200,775,000.00 |
| Total equity | 2.15B | 1.90B | 1.75B | 1.73B | 1.66B | 1.33B |
| Retained earnings | 2.31B | 2.03B | 1.88B | 1.86B | 1.80B | 1.47B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 230.67M | 217.89M | 327.07M | 355.48M | 188.79M | 224.46M | 395.10M | 152.13M |
| Depreciation & amortization | 39.70M | 38.31M | 43.05M | 45.09M | 45.54M | 47.24M | 48.09M | 49.24M |
| Free cash flow | 198.40M | 176.07M | 292.22M | 286.82M | 135.48M | 174.98M | 359.69M | 93.60M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -55.74M | -105.80M | -353.59M | -46.13M | -85.42M | -20.98M | -10.22M | -858.68M |
| Ending cash balance | 312.07M | 369.37M | 294.95M | 494.49M | 491.69M | 303.22M | 660.49M | 265.09M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -465.21M | 55.69M | 201.89M | 359.76M | -310.02M | 152.29M |
| Depreciation & amortization | 11.16M | 12.38M | 12.90M | 12.80M | 12.90M | 12.82M |
| Free cash flow | -483.01M | 38.27M | 186.98M | 351.37M | -320.64M | 141.03M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -182.64M | -354.04M | -234.21M | -87.79M | -126.83M | -393.21M |
| Ending cash balance | 151.12M | 152.83M | 145.97M | 265.09M | 198.28M | 163.75M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 11.86 | 15.27 | 14.58 | 15.75 | 14.43 | 15.01 | 13.21 | 13.57 |
| ROA %i | 6.50 | 8.40 | 7.58 | 7.99 | 7.43 | 8.37 | 8.09 | 7.64 |
| ROIC %i | 10.39 | 12.55 | 11.56 | 12.29 | 10.91 | 12.56 | 11.77 | 11.58 |
| 5-year avg ROE %i | 7.89 | 9.85 | 11.59 | 13.29 | 14.38 | 15.01 | 14.60 | 14.39 |
| EBIT margin %i | 11.59 | 13.08 | 11.47 | 11.46 | 10.16 | 10.68 | 9.67 | 10.36 |
| FCF / sales %i | 9.78 | 7.47 | 11.87 | 10.33 | 4.47 | 5.01 | 9.72 | 2.47 |
| Current ratioi | 2.00 | 1.92 | 1.69 | 1.91 | 1.96 | 1.74 | 1.95 | 1.56 |
| Quick ratioi | 1.90 | 1.81 | 1.57 | 1.79 | 1.85 | 1.65 | 1.86 | 1.44 |
| Debt / assetsi | 11.16 | 17.52 | 17.66 | 18.19 | 17.54 | 7.75 | 6.73 | 17.95 |
| LT debt / equityi | 19.69 | 30.35 | 31.98 | 33.68 | 31.92 | 11.29 | 9.21 | 34.00 |
| Interest coveragei | 8.65 | 16.02 | 14.25 | 15.68 | 30.64 | 26.01 | 51.46 | 18.34 |
| Revenue CAGR (3Y) %i | 4.46 | 9.13 | 10.83 | 11.04 | 8.79 | 12.34 | 10.03 | 7.75 |
| Net income CAGR (3Y) %i | 31.62 | 36.34 | 24.96 | 15.98 | 2.81 | 9.27 | 6.03 | 4.77 |
| FCF CAGR (3Y) %i | 22.28 | -4.88 | 36.21 | 13.07 | -8.37 | -15.71 | 7.84 | -11.60 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 12.46 | 12.33 | 13.30 | 13.57 | 13.99 | 15.63 |
| ROA %i | 7.85 | 7.29 | 7.59 | 7.64 | 7.78 | 7.19 |
| ROIC %i | 10.40 | 10.04 | 10.93 | 11.58 | 10.98 | 10.56 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 9.22 | 8.99 | 9.71 | 10.36 | 10.22 | 9.77 |
| FCF / sales %i | 4.26 | 1.89 | 1.19 | 2.47 | 6.61 | 9.14 |
| Current ratioi | 2.24 | 2.11 | 1.85 | 1.56 | 2.30 | 2.03 |
| Quick ratioi | 2.08 | 1.92 | 1.70 | 1.44 | 2.12 | 1.81 |
| Debt / assetsi | 10.79 | 19.65 | 21.09 | 17.95 | 27.64 | 34.74 |
| LT debt / equityi | 16.80 | 36.15 | 42.06 | 34.00 | 58.33 | 92.06 |
| Interest coveragei | 54.53 | 40.46 | 24.61 | 18.34 | 14.73 | 11.53 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Corporate Finance is the largest reported line at 41.41% of revenue, across 5 reported segments.
- No single line clears half of revenue; Forensic and Litigation Consulting (FLC) is next at 19.55%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Corporate Finance41.41%
Forensic and Litigation Consulting (FLC)19.55%
Economic Consulting19.01%
Strategic Communications10.06%
Technology9.97%
Quote time 2026-10-07 20:02:46 · For reference only, not investment advice and not tailored to your situation.